Objective:

To present significant research findings from Roswell Park Comprehensive Cancer Center at the ASCO annual meeting, highlighting their impact on cancer treatment.

Key Findings:

• GLP-1 receptor agonists may reduce the risk of developing HR+/HER2- breast cancer, as presented by Zunairah Shah.
• 40 million adults live in areas with limited access to clinical trials for gastrointestinal malignancies, as highlighted by Rahul Thakur.
• Older patients receiving CAR T-cell therapy may experience higher rates of adverse responses, as investigated by Jayasree Krishnan.
• AI models show potential in assisting clinical decisions in breast cancer, but benchmarking is limited, as evaluated by Mariam Haji Ahmad.

Interpretation:

Research highlights the potential of GLP-1s in breast cancer, challenges in CAR T accessibility, and the role of AI in clinical decision-making, emphasizing the need for further exploration.

Limitations:

• Limited geographic accessibility to clinical trials, impacting patient recruitment.
• Potential biases in real-world studies that may affect the validity of findings.
• Need for further validation of AI models to ensure reliability in clinical settings.

Conclusion:

Roswell Park's contributions at ASCO 2026 reflect ongoing advancements in cancer treatment and research, underscoring their role in shaping future cancer care.